Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.51 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 2/20 | 0.45 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.42 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29554593 | 1.00 | MAPT (0.52) | MAPTALDH1A1GAAL3MBTL1TAS1R3 | |
| SCHEMBL2153494 | 0.86 | ALDH1A1 (0.47) | MAPTALDH1A1GAAL3MBTL1TAS1R3 | |
| SCHEMBL4352652 | 0.84 | HTT (0.53) | MAPTALDH1A1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL703101 | 0.83 | TSHR (0.65) | MAPTALDH1A1L3MBTL1TAS1R3TAS1R1 | |
| SCHEMBL2972020 | 0.83 | TAS1R3 (0.51) | MAPTALDH1A1GAAL3MBTL1TAS1R3 | |
| SCHEMBL703716 | 0.83 | HPGD (0.53) | ALDH1A1L3MBTL1CYP2A6CYP1A2CYP3A4 | |
| SCHEMBL16953621 | 0.82 | TSHR (0.47) | MAPTALDH1A1GAAL3MBTL1TAS1R3 | |
| SCHEMBL8478583 | 0.82 | TSHR (0.64) | MAPTTSHRNPC1RAB9APKM | |
| SCHEMBL313211 | 0.82 | TSHR (0.64) | MAPTTSHRNPC1RAB9APKM | |
| SCHEMBL29655535 | 0.82 | TSHR (0.64) | MAPTTSHRNPC1RAB9APKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 194 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1242080-A4 | DOPAMINE TRANSPORTER INHIBITORS AND THEIR USE | UNIV GEORGETOWN (US) | 2003-01-22 | — | — | EP | claimed |
| EP-1242080-A1 | DOPAMINE TRANSPORTER INHIBITORS AND THEIR USE | GEORGETOWN UNIVERSITY (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001022964-A1 | DOPAMINE TRANSPORTER INHIBITORS AND THEIR USE | GEORGETOWN UNIVERSITY (US) | 2001-04-05 | — | — | WO | claimed |
| CN-118271158-B | Method for synthesizing deuterium-labeled substance containing deuterium atom structural unit | 山东大学 | 2026-05-12 | — | — | CN | disclosed |
| CN-115611883-B | PI3K alpha inhibitor with double-ring structure, and preparation method and application thereof | 生物岛实验室 | 2025-03-28 | — | — | CN | disclosed |
| CN-118271158-A | Method for synthesizing deuterium-labeled substance containing deuterium atom structural unit | 山东大学 | 2024-07-02 | — | — | CN | disclosed |
| CN-115611883-A | PI3K alpha inhibitor with bicyclic structure and preparation method and application thereof | 生物岛实验室 | 2023-01-17 | — | — | CN | disclosed |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FORMA THERAPEUTICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| CN-113329748-A | Inhibition of Fatty Acid Synthase (FASN) | 福马治疗股份有限公司 | 2021-08-31 | — | — | CN | disclosed |
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FORMA THERAPEUTICS, INC. | 2021-01-28 | — | — | US | disclosed |
| EP-0268112-A2 | A novel aromatic polyether and a process for producing a polyether | Asahi Kasei Kogyo Kabushiki Kaisha (JP) | 1988-05-25 | — | — | EP | disclosed |
| US-4592876-A | Arylglyoxals | AMERICAN CYANAMID COMPANY (US) | 1986-06-03 | — | — | US | disclosed |
| US-4517318-A | BENZOPHENONE AND TRANSITION METALCOMPOUNT ACCELERATOR | Sekisu Kagaku Kogyo Kabushiki Kaisha (JP) | 1985-05-14 | — | — | US | disclosed |
| US-4495315-A | BENZOPHENONE-TYPE COMPOUNDS AS DEGRADING AGENT- TRANSITION METAL ACCELERATORS | SEKISUI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1985-01-22 | — | — | US | disclosed |
| US-4474810-A | HYPOGLYCEMIC AGENTS, ANTIDIABETIC AGENTS | AMERICAN CYANAMID COMPANY (US) | 1984-10-02 | — | — | US | disclosed |
| EP-0114389-A2 | Substituted arylglyoxal derivatives | AMERICAN CYANAMID COMPANY (US) | 1984-08-01 | — | — | EP | disclosed |
| EP-0003895-A1 | 1-Acyl-3(5)-alkyl-5(3)-phenyl-1,2,4-triazoles, process for their preparation and pharmaceutical compositions containing them | E.R. Squibb & Sons, Inc. (US) | 1979-09-05 | — | — | EP | disclosed |
| US-4154843-A | Method of treating psychotic states with 1-acyl-3(5)-alkyl-5(3)-phenyl-1,2,4-triazoles | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
| US-4154841-A | Antiinflammatory 1-acyl-3(5)-alkyl-5(3)-phenyl-1,2,4-triazoles | E. R. SQUIBB & SONS, INC. (US) | 1979-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024508-A1 | INHIBITING FATTY ACID SYNTHASE (FASN) | FASN, SCD, FADS1 | MAPT 2981/4885ALDH1A1 1168/4885GAA 162/4885 |
| US-11299484-B2 | Inhibiting fatty acid synthase (FASN) | FASN, SCD, FADS1 | MAPT 2981/4885ALDH1A1 1168/4885GAA 162/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.